Alto Ingredients (ALTO) Aktievy
Alto Ingredients, Inc. producerar, distribuerar och marknadsför specialalkoholer, förnybara bränslen och viktiga ingredienser i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
ALTO klarat våra riskkontroller.
ALTO Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alto Ingredients, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$5.56 |
| 52 veckors högsta | US$6.11 |
| 52 veckors lägsta | US$0.92 |
| Beta | 0.14 |
| 1 månads förändring | 2.39% |
| 3 månaders förändring | 21.40% |
| 1 års förändring | 348.39% |
| 3 års förändring | 67.98% |
| 5 års förändring | -0.36% |
| Förändring sedan börsintroduktionen | -99.45% |
Senaste nyheter och uppdateringar
Seeking Alpha • Jun 25
Alto Ingredients: A Profitable Turnaround In Progress With Upside Potential
Summary Alto Ingredients is executing a successful turnaround, shifting to a leaner, more resilient business model with improved profitability and operational focus. Q1 2026 results highlighted strong profitability, robust crush margins, and material contributions from Section 45Z tax credits, supporting sustainable earnings momentum. ALTO’s valuation, growth, and momentum metrics significantly outperform sector medians, with 482% 1-year price performance and EBITDA growth of 696% YoY. I rate ALTO a buy, citing operational catalysts, reliable tax credit income, and ample liquidity to fund capital projects despite commodity and regulatory risks. Read the full article on Seeking AlphaAnalysartikel • Jun 18
Alto Ingredients (ALTO) Stock Could Be 44.3% Undervalued After $8.9 Million 45Z Credit Sale
Alto Ingredients (ALTO) has drawn fresh attention after monetizing its 2025 Section 45Z Clean Fuel Production Tax Credits, securing about $8.9 million in cash that ties directly to its low-carbon ethanol operations. See our latest analysis for Alto Ingredients. That cash injection from Section 45Z tax credits lands at a time when Alto Ingredients’ share price has risen 88.53% year to date, with a 30 day share price return of 6.25% and a one year total shareholder return of 332.33%. These...
Uppdatering av berättelse • Jun 18
ALTO: Stock Outlook Will Center On Future Clean Fuel Tax Credits
The analyst price target for Alto Ingredients has been revised from about $5.50 to roughly $10.00. Analysts attribute this change to updated assumptions on discount rates, profitability, and future P/E expectations.
Uppdatering av berättelse • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.Recent updates
Seeking Alpha • Jun 25
Alto Ingredients: A Profitable Turnaround In Progress With Upside Potential
Summary Alto Ingredients is executing a successful turnaround, shifting to a leaner, more resilient business model with improved profitability and operational focus. Q1 2026 results highlighted strong profitability, robust crush margins, and material contributions from Section 45Z tax credits, supporting sustainable earnings momentum. ALTO’s valuation, growth, and momentum metrics significantly outperform sector medians, with 482% 1-year price performance and EBITDA growth of 696% YoY. I rate ALTO a buy, citing operational catalysts, reliable tax credit income, and ample liquidity to fund capital projects despite commodity and regulatory risks. Read the full article on Seeking AlphaAnalysartikel • Jun 18
Alto Ingredients (ALTO) Stock Could Be 44.3% Undervalued After $8.9 Million 45Z Credit Sale
Alto Ingredients (ALTO) has drawn fresh attention after monetizing its 2025 Section 45Z Clean Fuel Production Tax Credits, securing about $8.9 million in cash that ties directly to its low-carbon ethanol operations. See our latest analysis for Alto Ingredients. That cash injection from Section 45Z tax credits lands at a time when Alto Ingredients’ share price has risen 88.53% year to date, with a 30 day share price return of 6.25% and a one year total shareholder return of 332.33%. These...Uppdatering av berättelse • Jun 18
ALTO: Stock Outlook Will Center On Future Clean Fuel Tax Credits
The analyst price target for Alto Ingredients has been revised from about $5.50 to roughly $10.00. Analysts attribute this change to updated assumptions on discount rates, profitability, and future P/E expectations.Uppdatering av berättelse • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.
Uppdatering av berättelse • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.Uppdatering av berättelse • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.Uppdatering av berättelse • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Uppdatering av berättelse • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Uppdatering av berättelse • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Uppdatering av berättelse • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Uppdatering av berättelse • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Uppdatering av berättelse • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Uppdatering av berättelse • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Uppdatering av berättelse • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Analysartikel • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Uppdatering av berättelse • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Analysartikel • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Analysartikel • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
Ny berättelse • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Analysartikel • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analysartikel • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysartikel • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Analysartikel • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysartikel • Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aktieägarnas avkastning
| ALTO | US Chemicals | US Marknad | |
|---|---|---|---|
| 7D | 7.1% | 2.8% | 1.6% |
| 1Y | 348.4% | 6.4% | 18.6% |
Avkastning vs industri: ALTO översteg US Chemicals branschen som gav 6.4 % under det senaste året.
Avkastning vs Marknaden: ALTO översteg US marknaden som gav 18.6 % under det senaste året.
Prisvolatilitet
| ALTO volatility | |
|---|---|
| ALTO Average Weekly Movement | 11.3% |
| Chemicals Industry Average Movement | 6.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: ALTO har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ALTO s veckovolatilitet ( 11% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2003 | 390 | Bryon McGregor | www.altoingredients.com |
Alto Ingredients, Inc. producerar, distribuerar och marknadsför specialalkoholer, förnybara bränslen och viktiga ingredienser i USA. Företaget är verksamt inom tre segment: Marketing and Distribution, Pekin Campus Production och Western Production. Företaget erbjuder specialalkoholer som används i munvatten, kosmetika, läkemedel, handdesinfektionsmedel, desinfektionsmedel och rengöringsmedel för hälso-, hem- och skönhetsmarknaderna, neutral sprit från spannmål som används i alkoholhaltiga drycker och vinäger samt majsgroddar som används i majsoljor på livsmedels- och dryckesmarknaderna; alkoholer och andra produkter för färgtillämpningar och gödningsmedel på industri- och jordbruksmarknaderna; och viktiga ingredienser, inklusive torkad jäst, majsproteinmjöl, majsproteinfoder, majsgroddar, destilleringsspannmål och flytande foder för kommersiella djurfoder och sällskapsdjursfoder, samt jäst och flytande CO2 för mänsklig konsumtion.
Alto Ingredients, Inc. Sammanfattning av grunderna
| ALTO grundläggande statistik | |
|---|---|
| Börsvärde | US$430.82m |
| Vinst(TTM) | US$28.02m |
| Intäkter(TTM) | US$916.07m |
15.4x
P/E-förhållande0.5x
P/S-förhållandeÄr ALTO övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ALTO resultaträkning (TTM) | |
|---|---|
| Intäkter | US$916.07m |
| Kostnad för intäkter | US$870.13m |
| Bruttovinst | US$45.94m |
| Övriga kostnader | US$17.92m |
| Intäkter | US$28.02m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.36 |
| Bruttomarginal | 5.01% |
| Nettovinstmarginal | 3.06% |
| Skuld/egenkapitalförhållande | 29.2% |
Hur har ALTO utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/05 12:31 |
| Aktiekurs vid dagens slut | 2026/07/02 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Alto Ingredients, Inc. bevakas av 9 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |